Accentia Biopharmaceuticals, Inc.

Calculating rank

USPTO Granted Patents = 4

% Expired Patents = 75.0

Forward Citations = 19

Loading Chart...

7 inventors (with patents filed for the assignee):

Francis E O'Donnell, Jr (4 out of 10 patents)

Carlos Santos (3 out of 18 patents)

Robert A Brodsky (2 out of 5 patents)

4. Susan Bonitz (2 out of 2 patents)

5. Richard John Jones (2 out of 8 patents)

6. Adam Kaplin (1 out of 2 patents)

7. Angelos M Stergiou (1 out of 2 patents)

4 patents: Sort by Forward Citations

1. 9279803 - Method of identifying patients not suitable for high-dose cyclophosphamide treatment (2016-03-08),

2. 9026372 - Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen (2015-05-05),

3. 8673321 - Cyclophosphamide in combination with anti-idiotypic vaccines (2014-03-18),

4. 8211460 - Formulations, devices and methods for treating and preventing mucositis (2012-07-03),

Company Overview

Accentia Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted therapies for serious respiratory and respiratory-related diseases. The company's pipeline includes innovative treatments for conditions such as cystic fibrosis and chronic obstructive pulmonary disease. With a commitment to improving patient outcomes and quality of life, Accentia is dedicated to advancing healthcare through cutting-edge research and development.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

4 Patents

#123 in Tampa, FL

#2,107 in Florida

#60,704 in US

Tampa, FL, United States of America